newsweek.ro/sanatate/recomandari-pentru-alegerea-t

The European Society for Medical Oncology (ESMO) has released updated guidelines for interpreting genetic alterations in cancer tumors and selecting targeted therapies. The new recommendations include more precise criteria for evaluating scientific evidence and a separate classification system for biomarkers indicating resistance to specific drugs. This aims to support personalized treatment decisions and enhance precision medicine in oncology. The revised ESCAT v2 system allows oncologists to assess the clinical relevance of molecular changes identified through tumor testing. Key updates include a detailed categorization of high-evidence levels and the introduction of a separate classification for resistance biomarkers, helping physicians avoid ineffective treatments and choose better therapeutic options.